{"generic":"Afamelanotide","drugs":["Afamelanotide"],"mono":{"0":{"id":"jymus0","title":"Generic Names","mono":"Afamelanotide"},"1":{"id":"jymus1","title":"Dosing and Indications","sub":[{"id":"jymus1b4","title":"Adult Dosing","mono":"<ul><li>Afamelanotide has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union.<\/li><li><b>Erythropoietic protoporphyria - Phototoxicity; Prophylaxis:<\/b> 1 implant SUBQ every 2 months prior to and during sunlight exposure; 3 implants\/year recommended; MAX 4 implants\/year (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"jymus1b5","title":"Pediatric Dosing","mono":"Safety and efficacy not established in patients younger than 18 years "},{"id":"jymus1b6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment:<\/b> Use contraindicated<\/li><li><b>Hepatic impairment or severe hepatic disease:<\/b> Use contraindicated<\/li><li><b>Elderly:<\/b> Not recommended in patients older than 70 years<\/li><\/ul>"},{"id":"jymus1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Erythropoietic protoporphyria - Phototoxicity; Prophylaxis<br\/>"}]},"3":{"id":"jymus3","title":"Contraindications\/Warnings","sub":[{"id":"jymus3b9","title":"Contraindications","mono":"<ul><li>Hepatic impairment<\/li><li>Hypersensitivity to afamelanotide or any component of the product<\/li><li>Renal impairment<\/li><li>Severe hepatic disease<\/li><\/ul>"},{"id":"jymus3b10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Patients with clinically significant cardiovascular disorders not studied; monitoring recommended<\/li><li>Dermatologic:<\/li><li>-- Maintain sun protection measures to manage photosensitivity according to skin type (Fitzpatrick scale)<\/li><li>-- Darkening of preexisting pigmentary lesions may occur; monitoring recommended<\/li><li>-- Use caution with individual or family history of melanoma or suspected or confirmed susceptibility to cutaneous melanoma<\/li><li>-- Use caution with individual history of basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, or other malignant or premalignant skin lesions<\/li><li>Endocrine and Metabolic:<\/li><li>-- Patients with clinically significant endocrine disorders (eg, diabetes, Cushing disease, Addison disease, Peutz-Jeghers syndrome) not studied; monitoring recommended<\/li><li>Gastrointestinal:<\/li><li>-- Patients with clinically significant gastrointestinal disorders not studied; monitoring recommended<\/li><li>Hematologic:<\/li><li>-- Patients with clinically significant hematological disorders, especially anemia, not studied; monitoring recommended<\/li><li>Neurologic:<\/li><li>-- Patients with clinically significant neurological disorders, including seizures, not studied; monitoring recommended<\/li><li>-- Driving and operating machines within 72 hours of use; somnolence and dizziness have been reported<\/li><li>Reproductive:<\/li><li>-- Women of childbearing potential; avoid pregnancy and use effective contraception during treatment and for 3 months thereafter<\/li><li>Respiratory:<\/li><li>-- Patients with clinically significant respiratory disorders not studied; monitoring recommended<\/li><li>Other:<\/li><li>-- Elderly patients (older than 70 years); use not recommended but if treated, monitoring required<\/li><\/ul>"},{"id":"jymus3b11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"jymus3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jymus5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Implant site reaction (21%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (19%), Vomiting (1% to less than 10%)<\/li><li><b>Neurologic:<\/b>Headache (20%)<\/li><\/ul><b>Serious<\/b><br\/><b>Immunologic:<\/b>Hypersensitivity reaction, At implant site (1% to less than 10%)<br\/>"},"6":{"id":"jymus6","title":"Drug Name Info","sub":{"2":{"id":"jymus6b19","title":"Class","mono":"Protectant, Dermatological<br\/>"},"3":{"id":"jymus6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jymus7","title":"Mechanism Of Action","mono":"Afamelanotide, an analogue of alpha-melanocyte stimulating hormone, activates eumelanin synthesis by binding to the melanocortin-1 receptor. Eumelanin contributes to photoprotection via multiple mechanisms, including strong broad band UV and visible light absorption (filter mechanism), scavenging free radicals (antioxidant activity), and inactivating superoxide anion and increasing superoxide dismutase availability (oxidative stress reduction).<br\/>"},"9":{"id":"jymus9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>Allow implant to warm to room temperature.<\/li><li>Disinfect skin above supra-iliac crest.<\/li><li>Insert 14-gauge catheter laterally, with the needle bevel facing upward, 1.5 to 2 cm into the subQ layer at a 30 to 45 degree angle.<\/li><li>Remove the needle and transfer the implant to the catheter outlet.<\/li><li>Using a stylet or other device, push the implant down the catheter lumen, then remove the catheter and device.<\/li><li>Palpate skin to confirm implant insertion.<\/li><li>Place a small pressure dressing to injection site.<\/li><li>Observe the patient for 30 minutes to watch for any hypersensitivity reaction.<\/li><\/ul>"},"10":{"id":"jymus10","title":"Monitoring","mono":"<ul><li>Absence of phototoxic side effects may indicate efficacy<\/li><li>Hematology, biochemistry, and vital signs after each implant administration, in patients with significant disorders of the gastrointestinal, cardiovascular, respiratory, endocrine, neurological, and hematological systems and the elderly<\/li><li>Allergic or hypersensitivity reactions; first 30 minutes after administration<\/li><li>Full body skin examinations; every 6 months<\/li><\/ul>"},"13":{"id":"jymus13","title":"Clinical Teaching","mono":"<ul><li>Warn female patient to avoid pregnancy during treatment and for 3 months following discontinuation.<\/li><li>Encourage patient to avoid activities requiring mental alertness or coordination until drug effects are realized due to potential for somnolence, fatigue, and dizziness.<\/li><li>Side effects may include headache, nausea, abdominal pain, vomiting, diarrhea, loss of appetite, flushing, skin discoloration or hyperpigmentation, back pain, or an implant site reaction.<\/li><li>Tell patient to report new or worsening skin lesions including a change in color.<\/li><\/ul>"}}}